Universität zu Köln

Cramer, Paula, Langerbeins, Petra and Hallek, Michael (2016). Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib. Cancer J., 22 (1). S. 62 - 67. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1540-336X

Full text not available from this repository.

Abstract

The landscape of treatment for chronic lymphocytic leukemia is rapidly changing at present. Considerable improvement has been achieved with the introduction of the anti-CD20 antibodies, and chemo-immunotherapy has now become an established standard for patients without the high-risk features del(17p)/TP53 mutation. Also, the outcome of patients with these adverse genetic aberrations was dramatically improved with the introduction of the kinase inhibitors ibrutinib and idelalisib. Different combinations of these and additional novel agents are currently evaluated in clinical trials. The combination of the Bruton tyrosine kinase inhibitor ibrutinib with an anti-CD20 antibody is an attractive option, because both drugs act synergistically: ibrutinib redistributes the CLL cells from their homing organs to the peripheral blood, and obinutuzumab eliminates the leukemic cells in the blood with particular efficiency. Adding the Bcl-2 antagonist venetoclax could further intensify the treatment of CLL. This combination might hold the potential to achieve a deep remission with an eradication of residual CLL cells and thus lead to long-term remissions of CLL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cramer, Paula UNSPECIFIED UNSPECIFIED UNSPECIFIED Langerbeins, Petra UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-290161
DOI:	10.1097/PPO.0000000000000174
Journal or Publication Title:	Cancer J.
Volume:	22
Number:	1
Page Range:	S. 62 - 67
Date:	2016
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1540-336X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; GENOMIC ABERRATIONS; FRONTLINE TREATMENT; INITIAL THERAPY; OPEN-LABEL; RITUXIMAB; CYCLOPHOSPHAMIDE; OFATUMUMAB; OBINUTUZUMAB Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/29016